Eleison Pharmaceuticals has received Orphan Drug Designation for ILC (Inhaled Lipid-complexed Cisplatin) from the European Commission, for the treatment of osteosarcoma. The designation follows the earlier positive opinion and recommendation of the European Medicines Agency (EMA) Committee of Orphan Medical Products. Orphan Drug Designation provides Eleison access to protocol assistance and certain financial incentives from the EMA, as well as 10 years marketing exclusivity for ILC upon the rec...